Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Free Report) have earned an average recommendation of “Buy” from the eleven research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $22.6667.
Several research analysts recently weighed in on the company. Morgan Stanley restated an “overweight” rating and set a $20.00 target price on shares of Trevi Therapeutics in a research note on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Monday, April 20th. Wall Street Zen upgraded Trevi Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Stifel Nicolaus set a $30.00 price objective on shares of Trevi Therapeutics in a report on Friday, May 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday, May 6th.
Read Our Latest Analysis on Trevi Therapeutics
Trevi Therapeutics Price Performance
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). On average, sell-side analysts expect that Trevi Therapeutics will post -0.47 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Hilton Head Capital Partners LLC lifted its stake in shares of Trevi Therapeutics by 32.6% during the first quarter. Hilton Head Capital Partners LLC now owns 4,250 shares of the company’s stock worth $51,000 after buying an additional 1,044 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Trevi Therapeutics by 20.5% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company’s stock valued at $70,000 after acquiring an additional 1,300 shares during the period. AlphaCentric Advisors LLC increased its position in shares of Trevi Therapeutics by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 23,970 shares of the company’s stock valued at $286,000 after acquiring an additional 1,303 shares during the period. Kennedy Capital Management LLC raised its stake in Trevi Therapeutics by 2.4% in the 4th quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company’s stock worth $704,000 after acquiring an additional 1,336 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Trevi Therapeutics by 32.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock worth $78,000 after acquiring an additional 1,523 shares during the last quarter. Hedge funds and other institutional investors own 95.76% of the company’s stock.
Trevi Therapeutics Company Profile
Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.
Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.
Featured Articles
- Five stocks we like better than Trevi Therapeutics
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
